In line with this, at best 1 out of 5 patients with triple negative breast cancer, the most common form of BRCA1 mutation-associated breast cancer, has been shown to benefit from single agent PD-1 blockade (38–40). This evidence concerns the gene BRCA1 and breast cancer.